IE43449L - Improving the compatability of gamma globulins. - Google Patents
Improving the compatability of gamma globulins.Info
- Publication number
- IE43449L IE43449L IE752826A IE282675A IE43449L IE 43449 L IE43449 L IE 43449L IE 752826 A IE752826 A IE 752826A IE 282675 A IE282675 A IE 282675A IE 43449 L IE43449 L IE 43449L
- Authority
- IE
- Ireland
- Prior art keywords
- gamma globulin
- solution
- compatability
- centrifuged
- precipitated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1495159 Gamma globulin PLASMESCO AG 29 Dec 1975 [2 Jan 1975] 53020/75 Heading A5B [Also in Division C3] The compatability of gamma globulin precipitated from blood or blood products is improved by dissolving the precipitated gamma globulin in an aqueous solution containing from 1 to 30% of a hydroxyethyl starch having a molecular weight of 1000 to 900000 and thereafter recovering the gamma globulin from this solution. In an example gamma globulin precipitate is dissolved in a buffered aqueous solution at pH 6.7 in a concentration of about 6%. About 10% of hydroxyethyl starch (M.W. 1000 to 900000) is added to this solution which facilitates separation of existing gamma globulin aggregates and simultaneously protects non-aggregated gamma globulin molecules. After addition of 10% of polyethyleneglycol the mixture is centrifuged. The remaining supernatant phase is mixed with 20% polyethylene glycol at pH 7.2 and centrifuged. The resulting precipitate is taken up in saline solution and is suitable for the therapeutic use.
[GB1495159A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2500076A DE2500076C3 (en) | 1975-01-02 | 1975-01-02 | Process for the production of intravenously tolerated gamma globulins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE43449L true IE43449L (en) | 1976-07-02 |
| IE43449B1 IE43449B1 (en) | 1981-02-25 |
Family
ID=5935911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2826/75A IE43449B1 (en) | 1975-01-02 | 1975-12-30 | Process reducing the anticomplementary activity of gamma globulins |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS5512001B2 (en) |
| AT (1) | AT344883B (en) |
| AU (1) | AU505416B2 (en) |
| BE (1) | BE837211A (en) |
| CA (1) | CA1058075A (en) |
| DD (1) | DD121875A5 (en) |
| DE (1) | DE2500076C3 (en) |
| DK (1) | DK144679C (en) |
| EG (1) | EG11987A (en) |
| ES (1) | ES443982A1 (en) |
| FR (1) | FR2296429A1 (en) |
| GB (1) | GB1495159A (en) |
| IE (1) | IE43449B1 (en) |
| IL (1) | IL48766A (en) |
| IN (1) | IN143525B (en) |
| NL (1) | NL179824C (en) |
| PL (1) | PL99599B1 (en) |
| SE (1) | SE437470B (en) |
| SU (1) | SU576898A3 (en) |
| ZA (1) | ZA758050B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604759C2 (en) * | 1976-02-07 | 1983-06-01 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Method of Obtaining IV Compatible Gamma Globulins |
| JPS6016406B2 (en) * | 1976-08-06 | 1985-04-25 | マイヤ−、ル−イス、コ−バル | Method for producing intravenously administrable gamma globulin and gamma globulin prepared thereby |
| US4124576A (en) * | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
| GB1603244A (en) * | 1977-05-20 | 1981-11-18 | Max Planck Gesellschaft | Medicaments for the suppression of pathological processes |
| JPS5822085B2 (en) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | Intravenous gamma globulin preparations |
| AT359641B (en) | 1978-09-19 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING AN INTRAVENOUS ADMINISTRABLE ANTIBODY-CONTAINING IMMUNOGLOBULIN PREPARATE |
| EP0019403B1 (en) * | 1979-05-10 | 1985-07-31 | American Hospital Supply Corporation | Hydroxyalkyl-starch drug carrier |
| US4396608A (en) * | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| EP0085747B2 (en) * | 1982-02-08 | 1990-05-30 | Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten | Intravenously administrable human immunoglobuline and process for its preparation |
| US4482483A (en) * | 1983-04-06 | 1984-11-13 | Armour Pharmceutical Company | Composition of intravenous immune globulin |
| SE8302483L (en) * | 1983-05-02 | 1984-11-03 | Pharmacia Ind | PROCEDURE FOR PURIFICATION OF BIOLOGICALLY ACTIVE SUBSTANCES |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| DE19907257A1 (en) * | 1999-02-21 | 2000-09-14 | Bernd Horst Meier | Means for controlling the diffusion of injection solutions |
| DE10040707A1 (en) * | 2000-08-17 | 2002-03-14 | Braun Melsungen Ag | Injectable aqueous medicament, containing colloid, e.g. hydroxyethyl starch, to modulate mobility, diffusion, pharmacokinetic and electrophoretic properties of active agent and improve effectiveness |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| RU2442793C2 (en) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES |
| PL1976877T5 (en) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (en) * | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| DE2234069A1 (en) * | 1971-07-16 | 1973-02-08 | South African Inventions | METHOD OF MANUFACTURING A PURIFIED GAMMA GLOBULIN |
| IL43643A (en) * | 1972-11-27 | 1976-10-31 | Baxter Laboratories Inc | Method for production of gamma globulin |
| JPS49101516A (en) * | 1973-01-13 | 1974-09-25 |
-
1975
- 1975-01-02 DE DE2500076A patent/DE2500076C3/en not_active Expired
- 1975-12-16 NL NLAANVRAGE7514627,A patent/NL179824C/en not_active IP Right Cessation
- 1975-12-18 SE SE7514388A patent/SE437470B/en not_active IP Right Cessation
- 1975-12-22 DK DK584375A patent/DK144679C/en active
- 1975-12-23 AT AT981675A patent/AT344883B/en active
- 1975-12-26 FR FR7539814A patent/FR2296429A1/en active Granted
- 1975-12-27 JP JP15974275A patent/JPS5512001B2/en not_active Expired
- 1975-12-29 GB GB53020/75A patent/GB1495159A/en not_active Expired
- 1975-12-29 DD DD190614A patent/DD121875A5/xx unknown
- 1975-12-30 ZA ZA00758050A patent/ZA758050B/en unknown
- 1975-12-30 IE IE2826/75A patent/IE43449B1/en unknown
- 1975-12-30 AU AU87921/75A patent/AU505416B2/en not_active Expired
- 1975-12-30 IN IN2413/CAL/75A patent/IN143525B/en unknown
- 1975-12-30 CA CA242,734A patent/CA1058075A/en not_active Expired
- 1975-12-30 ES ES443982A patent/ES443982A1/en not_active Expired
- 1975-12-30 BE BE6045314A patent/BE837211A/en not_active IP Right Cessation
- 1975-12-30 EG EG775/75A patent/EG11987A/en active
- 1975-12-30 IL IL48766A patent/IL48766A/en unknown
- 1975-12-31 SU SU7502306354A patent/SU576898A3/en active
-
1976
- 1976-01-01 PL PL1976186289A patent/PL99599B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE837211A (en) | 1976-06-30 |
| JPS5191321A (en) | 1976-08-10 |
| GB1495159A (en) | 1977-12-14 |
| AU505416B2 (en) | 1979-11-22 |
| DK144679B (en) | 1982-05-10 |
| ZA758050B (en) | 1976-12-29 |
| NL7514627A (en) | 1976-07-06 |
| ATA981675A (en) | 1977-12-15 |
| CA1058075A (en) | 1979-07-10 |
| IN143525B (en) | 1977-12-17 |
| DE2500076C3 (en) | 1982-11-18 |
| FR2296429A1 (en) | 1976-07-30 |
| SE7514388L (en) | 1976-07-05 |
| DE2500076A1 (en) | 1976-07-08 |
| SU576898A3 (en) | 1977-10-15 |
| JPS5512001B2 (en) | 1980-03-29 |
| IE43449B1 (en) | 1981-02-25 |
| NL179824C (en) | 1986-11-17 |
| FR2296429B1 (en) | 1978-12-01 |
| PL99599B1 (en) | 1978-07-31 |
| AT344883B (en) | 1978-08-10 |
| SE437470B (en) | 1985-03-04 |
| EG11987A (en) | 1981-12-31 |
| IL48766A0 (en) | 1976-02-29 |
| ES443982A1 (en) | 1977-07-16 |
| DK584375A (en) | 1976-07-03 |
| NL179824B (en) | 1986-06-16 |
| DE2500076B2 (en) | 1979-02-22 |
| DD121875A5 (en) | 1976-09-05 |
| AU8792175A (en) | 1977-07-14 |
| DK144679C (en) | 1982-10-11 |
| IL48766A (en) | 1979-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE7514388L (en) | PROCEDURE FOR IMPROVING THE INTROVENOSTOLERANCE OF GAMMA GLOBULINS | |
| Chazotte et al. | Further studies on F1-ATPase inhibition by local anesthetics | |
| ES8506758A1 (en) | An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof. | |
| DK0678097T3 (en) | Newly known colonic or ileum-specific steroid derivatives | |
| FI844557L (en) | CONCENTRATES OF ANTIHEMOFILFACTOR VIII AND FAR CONTENT FOR FRAMSTATION OF DETSAMMA. | |
| GB1375811A (en) | ||
| GB1418849A (en) | Production of antisera | |
| GB1442283A (en) | Orally applicable immunoglobulin composition | |
| GB779493A (en) | Process for the isolation of stable, highly purified gamma globulin preparations | |
| EP0096007A3 (en) | Pharmaceutical preparation containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them | |
| KR890002103A (en) | Piperidine Derivatives, Preparations and Dorjival 38 | |
| GB1436529A (en) | Process for preparing a blood fraction | |
| ATE59144T1 (en) | PROCESS FOR THE PREPARATION OF GAMMA GLOBULIN FOR INTRAVENOUS USE. | |
| IE34609L (en) | Therapeutic substituted thiazolidinedione | |
| Boyce et al. | Total nondialyzable solids (TNDS) in human urine. IV. Electrophoretic properties of RS-1 subfraction | |
| GB1290381A (en) | ||
| IE39676B1 (en) | Complex compound comprising dna | |
| GB1353847A (en) | Process for removal of particle-forming proteins from blood | |
| US3897551A (en) | Iodoglucagons and process for prolonging the biological activity of glucagon | |
| Lewis et al. | Erythropoietic Activity in Human Urine Concentrate. | |
| GB1302353A (en) | ||
| IE39800L (en) | 4-amino-3-hydrazino-1,2,4-triazole derivatives | |
| GB1384684A (en) | 1,3,5-triazine and process for the preparation thereof | |
| HUT41632A (en) | Process for preparing agents for the enhancement of protein absorption | |
| GB1509445A (en) | Benzodiazepine derivatives and a process for the preparation thereof |